These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17233530)

  • 21. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
    Tseng SL; Hung MS; Chang CP; Song JS; Tai CL; Chiu HH; Hsieh WP; Lin Y; Chung WL; Kuo CW; Wu CH; Chu CM; Tung YS; Chao YS; Shia KS
    J Med Chem; 2008 Sep; 51(17):5397-412. PubMed ID: 18712856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.
    Zhang Y; Burgess JP; Brackeen M; Gilliam A; Mascarella SW; Page K; Seltzman HH; Thomas BF
    J Med Chem; 2008 Jun; 51(12):3526-39. PubMed ID: 18512901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.
    Fulp A; Bortoff K; Zhang Y; Seltzman H; Snyder R; Maitra R
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5711-4. PubMed ID: 21875798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.
    Fay JF; Farrens DL
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric modulation of the cannabinoid CB1 receptor.
    Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA
    Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
    Fan H; Kotsikorou E; Hoffman AF; Ravert HT; Holt D; Hurst DP; Lupica CR; Reggio PH; Dannals RF; Horti AG
    Eur J Med Chem; 2009 Feb; 44(2):593-608. PubMed ID: 18511157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.
    Cichero E; Menozzi G; Spallarossa A; Mosti L; Fossa P
    J Mol Model; 2008 Dec; 14(12):1131-45. PubMed ID: 18696129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
    Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
    Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor.
    Scott CE; Ahn KH; Graf ST; Goddard WA; Kendall DA; Abrol R
    J Chem Inf Model; 2016 Jan; 56(1):201-12. PubMed ID: 26633590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes.
    Grant PS; Kahlcke N; Govindpani K; Hunter M; MacDonald C; Brimble MA; Glass M; Furkert DP
    Bioorg Med Chem Lett; 2019 Nov; 29(21):126644. PubMed ID: 31564385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
    Lazzari P; Distinto R; Manca I; Baillie G; Murineddu G; Pira M; Falzoi M; Sani M; Morales P; Ross R; Zanda M; Jagerovic N; Pinna GA
    Eur J Med Chem; 2016 Oct; 121():194-208. PubMed ID: 27240274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists.
    Szabó G; Kiss R; Páyer-Lengyel D; Vukics K; Szikra J; Baki A; Molnár L; Fischer J; Keseru GM
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3471-5. PubMed ID: 19457667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal Structure of the Human Cannabinoid Receptor CB
    Hua T; Vemuri K; Pu M; Qu L; Han GW; Wu Y; Zhao S; Shui W; Li S; Korde A; Laprairie RB; Stahl EL; Ho JH; Zvonok N; Zhou H; Kufareva I; Wu B; Zhao Q; Hanson MA; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
    Cell; 2016 Oct; 167(3):750-762.e14. PubMed ID: 27768894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.
    Madsen MV; Peacock L; Werge T; Andersen MB
    J Psychopharmacol; 2006 Sep; 20(5):622-8. PubMed ID: 16533866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of type 1 cannabinoid receptor allosteric ligands.
    Alaverdashvili M; Laprairie RB
    Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.